Medicare couldn't cover Wegovy for weight loss. But now that it's also a heart drug, the door is open

Novo Nordisk's newly won permission to market the heart benefits of its obesity drug Wegovy could provide a backdoor way to expand access to the drug for people on Medicare, experts told STAT.

You are viewing a robot-friendly page.Click hereto reload in standard format.